Literature DB >> 18498783

Temporal trends in the management of potentially resectable lung cancer.

Farhood Farjah1, Douglas E Wood, David Yanez, Rebecca G Symons, Bahirathan Krishnadasan, David R Flum.   

Abstract

BACKGROUND: Standardized, evidence-based guidelines recommend lung resection for patients with stage I or II nonsmall-cell lung cancer (NSCLC), and select patients with stage IIIA disease. We hypothesized that the proportion of patients operated on would increase over time coincident with increasing adherence to practice guidelines and improved patient/provider education over time.
METHODS: This investigation was a cohort study of tumor-registry data linked to Medicare claims.
RESULTS: Between 1992 and 2002, 24,030 patients--mean age 75 +/- 6 years, 55% men--were diagnosed with NSCLC. In each stage, the proportion of patients undergoing resection was lower in 2002 compared with 1992: stage I (68% versus 80%, p < 0.001), II (59% versus 74%, p < 0.001), and IIIA (23% versus 35%, p < 0.001). The mean age and comorbidity index of the cohort was higher in 2002 compared with 1992 (76 versus 74 years, p < 0.001; and 0.47 and 0.82, p < 0.001, respectively). The unadjusted odds of resection decreased by 6% per year (odds ratio 0.94, 99% confidence interval: 0.93 to 0.95), and adjustment for age, comorbidity index, race, and stage resulted in a slightly smaller (4% per year) but significantly decreasing trend in operative management over time (odds ratio 0.96, 99% confidence interval: 0.95 to 0.97).
CONCLUSIONS: Unexpectedly, the use of resection for lung cancer has decreased dramatically over time, and this decline is not fully accounted for by an older cohort with more comorbid conditions. Future investigations should determine whether increasing unmeasured contraindications to resection, barriers to accessing specialty care, an inadequate supply of thoracic surgeons, or bias against operative therapy are responsible.

Entities:  

Mesh:

Year:  2008        PMID: 18498783     DOI: 10.1016/j.athoracsur.2007.12.081

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  9 in total

1.  Pattern of Imaging after Lung Cancer Resection. 1992-2005.

Authors:  Gulshan Sharma; Shawn P E Nishi; Yu-Li Lin; Yong-Fang Kuo; James S Goodwin; Taylor S Riall
Journal:  Ann Am Thorac Soc       Date:  2016-09

2.  Identifying specific chemotherapeutic agents in Medicare data: a validation study.

Authors:  Jennifer L Lund; Til Stürmer; Linda C Harlan; Hanna K Sanoff; Robert S Sandler; Maurice Alan Brookhart; Joan L Warren
Journal:  Med Care       Date:  2013-05       Impact factor: 2.983

Review 3.  A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation-part 1: a guide to decision-making.

Authors:  Frank C Detterbeck; Justin D Blasberg; Gavitt A Woodard; Roy H Decker; Ulas Kumbasar; Henry S Park; Vincent J Mase; Brett C Bade; Andrew X Li; Whitney S Brandt; David C Madoff
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

4.  Microsimulation model predicts survival benefit of radiofrequency ablation and stereotactic body radiotherapy versus radiotherapy for treating inoperable stage I non-small cell lung cancer.

Authors:  Angela C Tramontano; Lauren E Cipriano; Chung Yin Kong; Jo-Anne O Shepard; Michael Lanuti; G Scott Gazelle; Pamela M McMahon
Journal:  AJR Am J Roentgenol       Date:  2013-05       Impact factor: 3.959

5.  Benefit of adjuvant chemotherapy after resection of stage II (T1-2N1M0) non-small cell lung cancer in elderly patients.

Authors:  Mark F Berry; Brooke K Coleman; Lesley H Curtis; Mathias Worni; Thomas A D'Amico; Igor Akushevich
Journal:  Ann Surg Oncol       Date:  2014-09-06       Impact factor: 5.344

6.  Variability in the treatment of elderly patients with stage IIIA (N2) non-small-cell lung cancer.

Authors:  Mark F Berry; Mathias Worni; Ricardo Pietrobon; Thomas A D'Amico; Igor Akushevich
Journal:  J Thorac Oncol       Date:  2013-06       Impact factor: 15.609

7.  Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer.

Authors:  Ben C Creelan; Scott Antonia; Gerold Bepler; Timothy J Garrett; George R Simon; Hatem H Soliman
Journal:  Oncoimmunology       Date:  2013-03-01       Impact factor: 8.110

8.  Lung Cancer Patient and Caregiver Health Vulnerabilities and Interest in Health Promotion Interventions: An Exploratory Study.

Authors:  Chandylen L Nightingale; Laurie E Steffen; Janet A Tooze; William Petty; Suzanne C Danhauer; Hoda Badr; Kathryn E Weaver
Journal:  Glob Adv Health Med       Date:  2019-07-17

9.  Barriers to surveillance imaging adherence in early-staged lung cancer.

Authors:  Ian C Bostock; Wayne Hofstetter; Reza Mehran; Ravi Rajaram; David Rice; Boris Sepesi; Stephen Swisher; Ara Vaporciyan; Garrett Walsh; Mara B Antonoff
Journal:  J Thorac Dis       Date:  2021-12       Impact factor: 2.895

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.